reports
Allogene Therapeutics Reports Favorable Result for Servier in Arbitrat...
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene T...
Allogene Therapeutics Announces Participation in Upcoming Investor Con...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December. TD Cowen’s Immunology & Inflammation Virtual SummitWednesday, November 121:30PM PT/4:30PM ET Jefferies Global Healthcare Conference in LondonTuesday, November ...
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and...
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Australia and South Korea Expected to Open in early 2026Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harness...
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presen...
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Fl...
Allogene Therapeutics to Report Third Quarter 2025 Financial Results a...
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the third quarter 2025 financial results and provide a business update on November 6, 2025, after the close of the market. ...
Allogene Therapeutics Announces Participation in Upcoming Investor Con...
Allogene Therapeutics Announces Participation in Upcoming Investor Conference SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September. Citi's 2025 Biopharma Back to School SummitWednesday, September 37:30AM PT/10:30AM ET Any available webcasts will be posted to the Company's website at under the Investors t...
Allogene Therapeutics Reports Second Quarter 2025 Financial Results an...
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion vs. ObservationMore than 50 sites Activated Across the U.S. and Canada, with Additional International Expansion Underway; Scheduled Futility Analysis Remains on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmu...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cycl...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion ArmUnplanned Review of Safety and Biomarker Data with Standard FC and Cema-cel Indicates Encouraging MRD Conversion Rat...
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durab...
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO Data Highlights Transformative Promise of CAR T in Solid TumorsPhase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response RateFour of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of A...
Allogene Therapeutics Announces Participation in Upcoming Investor Con...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in four upcoming investor conferences in May and June. TD Cowen’s 6th Annual Oncology Innovation Summit: Insights for ASCO & EHATuesday, May 279:30AM PT/12:30PM ET Jefferies Global Healthcare ConferenceWednesday, June 41:55P...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuri...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of two abstracts on the American Society of Clinical Oncology (ASCO) website in advance of the 2025 ASCO Annual Meeting, taking place May 30-June 3 in Chicago,...
Allogene Therapeutics Reports First Quarter 2025 Financial Results and...
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Co...
Allogene Therapeutics to Report First Quarter 2025 Financial Results a...
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the first quarter 2025 financial results and provide a business update on May 13, 2025, after the close of the market. The annou...
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in ...
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present updated data from the completed Phase 1 TRAVERSE trial of ALLO-316 in an oral pre...
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO...
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION Basket Study of ALLO-329 in RheumatologyDual CD19/CD70 CAR T Specifically Designed to Enhance Therapeutic Benefit, Expanding Treatment Potential Across a Range of Autoimmune IndicationsLeverages Proprietary Dagger® Technology to Reduce or Eliminate Lymphodepletion, Potentially Expanding Access to a Broader P...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financ...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Ongoing Pivotal Phase 2 ALPHA3 Trial Advancing with Site Activation and Patient EnrollmentLymphodepletion Selection and Futility Analysis Anticipated Around Mid-2025Primary EFS Data Expected Around YE 2026 with Potential BLA Submission in 2027 ALLO-329 in Autoimmune Disease (AID) Secured Investigational New Drug (IN...
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Fina...
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update Conference Call and Webcast Scheduled for March 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, af...
Allogene Therapeutics Announces Participation in March Investor Confer...
Allogene Therapeutics Announces Participation in March Investor Conference SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in March. TD Cowen 45th Annual Health Care ConferenceWednesday, March 5, 20258:20AM PT/11:50AM ET Any available webcasts will be posted to the Company's website at under the Investors tab in...
Allogene Therapeutics Expands Strategic Partnership with Foresight Dia...
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced an expanded strategic collaboration with Foresight Diagnostics, Inc. to include the development of Foresight’s minimal residual disease (MRD) assay as a c...
Allogene Therapeutics Announces Publication of Durable Response Data f...
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology Efficacy Comparable to Approved Autologous CD19 CAR Ts: Achieved Overall Response (ORR) and Complete Response (CR) Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, RespectivelyDurability of Response: Among Patients Who Achieved CR, Median Duration of Response (DOR) of 23.1 Months and Median Overall Survival (OS) Not Re...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.